CDMOs Biovian and 3P eye global strategy through merger

As per the agreement, Biovian and 3P will still have their legal entities and independent manufacturing sites. With the initiative of the common shareholder, Keensight Capital, the companies are now combined under the same group called, 3PBiovian, and will continue operating under that Group entity going forward, but specific financials have not been disclosed.

3PBiovian will provide a range of services including microbial and mammalian protein expression, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production, along with fill and finish services for recombinant proteins and viral vectors.

“With 3PBiovian’s combined capabilities and capacities, we can better address the complex needs of the biologics market in the US territory,” a spokesperson for 3PBiovian told Bioprocess Insider. 

“From the perspective of Biovian’s and 3P’s clients, this means access to extensive technologies, improved timelines and enhanced service quality for biopharmaceutical development and manufacturing. […] 3P’s commercial office in Boston will serve as a hotspot for Biovian’s US West Coast and East Coast leaders.” 

3PBiovian aims to benefit from the already-established presence of both companies in the US market, enabling them to develop a comprehensive portfolio that caters to the specific needs of clients. 

The combined entity also hopes to target the European CDMO market to maximize its growth potential through addressing unmet clinical needs of patients, the firm said. The two companies will enable 3PBiovian to address complex customer needs at all stages of the development cycle from early discovery to commercial manufacturing. 

Additionally, the firm confirmed it is “currently in advanced negotiations for several significant projects and anticipate their successful closure soon. Our ongoing global and service expansions indicate a strategic focus on attracting new biopharmaceutical clients seeking comprehensive solutions in biologics development and manufacturing.” 

Functional across 15,800 square-meters of manufacturing sites, the firm will retain 550 employees from Biovian and 3P and confirm combined annual sales of more than $75 million. 

The combined entity will be led by Dámaso Molero Sánchez (former 3P CEO) as CEO, Antti Nieminen (former Biovian CEO) as deputy CEO, Heidi Suuronen as CFO, and Elena Erroba as chief commercial officer.